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ABSTRACT
Objectives: The present study aimed to evaluate the
frequency of warning signs in younger patients with
stroke with a special regard to the ‘FAST’ scheme, a
public stroke recognition instrument (face, arm, speech,
timely).
Setting: Primary stroke care in participating centres of a
multinational European prospective cross-sectional study
(Stroke in Young Fabry Patients; sifap1). Forty-seven
centres from 15 European countries participate in sifap1.
Participants: 5023 acute patients with stroke
(aged 18–55 years) patients (96.5% Caucasians) were
enrolled in the study between April 2007 and January
2010.
Primary and secondary outcome measures: sifap1
was originally designed to investigate the relation of
juvenile stroke and Fabry disease. A secondary aim of
sifap1 was to investigate stroke patterns in this specific
group of patients. The present investigation is a
secondary analysis addressing stroke presenting
symptoms with a special regard to signs included in the
FAST scheme.
Results: 4535 patients with transient ischaemic attack
(TIA; n=1071), ischaemic stroke (n=3396) or other
(n=68) were considered in the presented analysis. FAST
symptoms could be traced in 76.5% of all cases. 35% of
those with at least one FAST symptom had all three
symptoms. At least one FAST symptom could be
recognised in 69.1% of 18–24 years-old patients, in 74%
of those aged 25–34 years, in 75.4% of those aged
35–44 years, and 77.8% in 45–55 years-old patients.
With increasing stroke severity signs included in the
FAST scheme were more prevalent (National Institute of
Health Stroke Scale, NIHSS<5: 69%, NIHSS 6–15:
98.9%, NIHSS>15: 100%). Clustering clinical signs
according to FAST lower percentages of strokes in the
posterior circulation (65.2%) and in patients with TIA
(62.3%) were identified.
Conclusions: FAST may be applied as a useful and
rapid tool to identify stroke symptoms in young
individuals aged 18–55 years. Especially in patients
eligible for thrombolysis FAST might address the majority
of individuals.
Study registration: The study was registered in http://
www.clinicaltrials.gov (No. NCT00414583).
INTRODUCTION
Getting patients with stroke to the acute care
hospital on time is the major requirement for
effective stroke therapy. Knowing warning
signs of stroke is the ﬁrst and most important
Strengths and limitations of this study
▪ The present analysis investigated clinical symp-
toms in young patients with stroke, participants
in a unique prospectively collected population of
young (18–55 years) stroke victims (Stroke in
Young Fabry Patients study; sifap1). A special
focus was the analysis of symptoms included in
the (face, arm as well as speech and time) FAST
scheme. The FAST message is a tool used in
awareness campaigns to propagate clinical sign
of stroke; it includes weakness of the face and
arm, as well as speech and essentially time.
▪ The main finding indicates that nearly one-
quarter of young strokes is not targeted by the
FAST scheme. However, FAST signs are more
frequent in patients with acute stroke eligible for
thrombolysis. This might be due to increasing
stroke severity.
▪ The main purpose of sifap1 was not to validate a
stroke recognition instrument. The ‘FAST
wording’ was primarily not covered with a spe-
cific slot in the case report form. FAST items
were derived from different sources after the
cerebrovascular event (eg, after employing the
NIH Stroke Scale immediately after hospital
admission). This limitation need to be taken into
account when interpreting our results.
▪ However, clustering clinical signs according to
FAST the majority of patients included in the
sifap1 study are targeted. Therefore, FAST may
be applied as a useful and rapid tool to identify
stroke symptoms in young individuals aged 18–
55 years.
▪ Since risk factors and aetiology profiles in the
sifap1 cohort resembled those found in elderly
patients with stroke, conclusions from our study
may be also valid in older age groups.
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step in a complex chain towards timely treatment manage-
ment. Effective public education follows simple rules: the
message must be simple to remember, effective and con-
sistent. For this purpose different stroke recognition instru-
ments with different symptoms and different wording have
been developed,1–6 offering criteria to identify stroke for
public education.1–3 7–9 They are useful for identifying
strokes in public,5 9 for triage by ambulance parame-
dics,2 3 6 to guide paramedics and emergency physicians to
direct patients with acute neurological signs to appropriate
care for emergency room physicians1 2 or as a screening
instrument in prehospital stroke research.6 Selection and
number of alarming symptoms as well as wording differ;
three to six warning signs are usually promoted. Currently
many distinguished awareness campaigns to propagate the
signs of stroke use the simpliﬁed FAST message,9 which
adopts weakness of face, arm as well as speech and essen-
tially time (National Health Service: ‘When stroke strikes
act FAST’). Although the mnemonic FAST is most fre-
quently adopted, there are so far no prospective multicen-
tre studies from large cohorts, which evaluate distinct
stroke signs for the use in public campaigns.
The aim of the present study is to investigate symp-
toms in acute young patients with stroke with a special
focus on signs included in the FAST scheme in a large
cohort of younger patients with stroke the Stroke in
Young Fabry Patients study (sifap1) and to analyse
factors which inﬂuence the usefulness in identifying
cerebrovascular events (CVEs).10 This is a secondary ana-
lysis of the sifap1 data which was originally supposed to
investigate the relation of juvenile stroke and a genetic
disorder known as Fabry disease. Fabry disease is an X
linked storage disorder which might affect the entire
body. In sifap1 in 0.9% of all patients Fabry disease was
identiﬁed.11
METHODS
The protocol of the sifap1 study was published recently.10
Described brieﬂy, the sifap1 study was designed as a multi-
center multinational prospective observational study
of young patients with stroke across Europe (table 1).
A total of 5023 patients with stroke (aged 18–55 years)
were enrolled in the sifap1 study, 271 patients with primary
haemorrhages and 217 patients without classiﬁcation of
the CVE were excluded. All patients or legal representa-
tives gave written consent to inclusion. The remaining
cohort of 4535 patients was extensively analysed including
detailed medical history, sociodemographics, clinical
characteristics, stroke severity, laboratory values, genetics,
cardiac work up as well as presenting symptoms on hos-
pital admission. Neurological deﬁcits were measured at
the time of maximum impairment according to previous
hospital-based stroke registers.12 A transient ischaemic
attack (TIA) was deﬁned as a CVE with clinical symptoms
lasting <24 h. Cerebral MRI with standardised MRI
sequences was a mandatory procedure. Images were
assessed centrally at the Department of Neurology,
Medical University of Graz, Austria, blinded to clinical and
demographic data. Items according to FAST were con-
structed as follows:
Face: facial palsy (minor asymmetry, partial or com-
plete) according to NIHSS item (the scale was assessed
within 48 h after admission).
Arm/paresis: left or right arm some effort against
gravity, no effort against gravity or no movement accord-
ing to NIHSS item (the scale was assessed within 48 h
after admission) or paresis in arm or leg according to
presenting symptoms (documented on inclusion in the
study).
Speech: severe aphasia or mute according to NIHSS
(documented on inclusion in the study), or dysarthria
(mid-moderate slurring, or severe, nearly intelligible or
worse) according to NIHSS (documented on inclusion
in the study) or dysphasia or aphasia or dysarthria
according to presenting symptoms (documented on
inclusion in the study).
Based on MRI data clinical signs addressed by FAST
were analysed in relation to the different vascular terri-
tories. Anterior circulation included the anterior and
middle cerebral artery, the posterior circulation the
vertebra-basilar territory and posterior cerebral artery.
Apart from NIHSS, the following presenting symptoms
were recorded additionally in the case report form on
inclusion: headache, nausea-vomiting, hemianopia, dip-
lopia and vertigo. According to the case report form
(CRF) 210 out of 1537 patients underwent intravenous
thrombolysis. Information about thrombolysis was
missing for 2999 patients because this item was included
later and not asked for all patients. The indication for
thrombolysis was left to the participating centres, accord-
ing to their local structured operating procedures.
Frequencies of presenting symptoms were analysed in
two modiﬁcations. At ﬁrst the number of cases exhibit-
ing FAST symptoms, that is, face palsy or problems with
Table 1 Inclusion criteria of patients in sifap110
Age 18–55 years
Diagnosis Acute CVE of any aetiology (ischaemic
stroke, TIA, intracranial haemorrhage)
Time since event Less than 3 months before inclusion in
the study
Verification of
diagnosis
Verification of brain infarction or
haemorrhage by MRIIn case of
negative MRI diagnosis confirmed by
stroke-experienced neurologist (more
than 2 years of experience in stroke
and at least 6 years of experience in
general neurology)
Diagnostic
information
MRI documentation
availableDiagnostic procedures
according to EUSI/ESO
recommendations
CVE, cerebrovascular event; TIA, transient ischaemic attack.
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arm/paresis or speech were simply calculated as percent-
age from the whole cohort. Additionally a Venn diagram
was plotted for those with at least one FAST symptom to
check frequencies of combinations of symptoms.
Alternatively, the frequency of each symptom was calcu-
lated in a sequential approach. After sizing the most fre-
quent symptom, the second frequent symptom was
extracted from the remaining cases and so on. This
approach allows establishing a ‘hierarchy’ of stroke signs
with regard to those symptoms that most often occur
aiming to identify as many as possible patients with stroke
employing as few symptoms as possible to create a compre-
hensive public message.
To test differences in subgroups according to age, sex
or severity of stroke we used multilevel logistic models to
account for the heterogeneity between centres. All ana-
lyses were calculated using commercially available soft-
ware: PASW Statistics 18, Release V.18.0.2 (copyright
SPSS, Inc. 2009, Chicago, Illinois, USA) and SAS soft-
ware, V.9.2 of the SAS System for Windows (copyright
2008 SAS Institute Inc. Cary, North Carolina, USA).
RESULTS
Frequency of presenting symptoms
A total of 5024 patients were enrolled in the study
between 2007 and 2010. A total of 4535 patients with
TIA (n=1071), ischaemic stroke (n=3396) or other
(n=68, refers to cerebral vein thrombosis or no docu-
mented entity) were included in the analysis. In general
76.5% of the young strokes included in sifap1 had clin-
ical signs covered by FAST criteria. Table 2 speciﬁes the
frequency of FAST symptoms according to gender and
age. Face was more frequently affected in men. FAST
signs were more prevalent in older age groups; this dif-
ference becomes even more obvious in younger patients
below 25 years where the capture rate of FAST signs is
below 70%.
Figure 1 shows the frequency of combinations of FAST
symptoms; 34.7% of those with at least one FAST symptom
have all three symptoms; 17.3% have only arm problems or
paresis; 16.6% have only speech problems and 15.7% have
both arm problems/paresis and speech problems. The iso-
lated symptom ‘Face’ is very rare (2.5%).
Symptoms which were registered in the sifap1 cohort
but were not considered for FAST are listed in table 3.
These stroke symptoms (not included in FAST) also dis-
closed age and gender differences: headache and
nausea were more common in women even after con-
trolling for migraine and age (results not shown),
whereas hemianopia, headache, nausea and somatosen-
sory deﬁcits were more common in younger age groups
even after controlling for migraine and sex (results not
presented).
With increasing stroke severity signs included in the
FAST scheme were more prevalent (table 4). FAST signs
were less frequent in TIA than in strokes (62.3% vs
81.5%). Severe strokes were nearly completely covered
by FAST signs when a NIH score of at least 6 was
present. FAST signs occurred in 96.7% of patients who
received thrombolysis.
Association between presenting symptoms and MRI
lesions
A total of 1419 patients had no infarct in MRI, more
than half of those patients (56.5%) had a TIA. From
those 1419 patients only 65.1% were detected by the
FAST items. For 252 patients no information about
Table 2 Frequency of presenting symptoms according to FAST stratified by gender and age
All
n=4535
Men
n=2675
Women
n=1860
p Value
18–24
n=136
25–34
n=443
35–44
n=1250
45–55
n=2706
p ValuePer cent Per cent Per cent Per cent Per cent Per cent Per cent
Face 38.5 40.4 35.8 0.002 29.4 34.1 36.8 40.5 <0.001
Arm/paresis 57.7 58.9 56.0 0.062 50.0 56.2 54.8 59.7 0.002
Speech 55.4 57.4 52.6 0.062 47.1 53.3 54.8 56.5 0.014
Total* 76.5 77.2 75.4 0.072 69.1 74.0 75.4 77.8 0.002
*Total subsumes patients (%) identified by one or more of the indicated stroke signs
FAST, face, arm, speech, timely.
Figure 1 Venn diagram of FAST symptoms in those with at
least one symptom (n=3469).
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lesions in MRI was available. For patients with deﬁnite
infarct lesions in MRI (n=2865) we tested the differences
in occurrence of symptoms included in the FAST
scheme regarding vascular territories: FAST symptoms
were less frequent in patients with strokes in the poster-
ior circulation, where only 65.2% of all cases with an
apparent MRI lesion could be identiﬁed, whereas 92.4%
of anterior circulation strokes matched symptoms
included in the FAST criteria. There was no difference
between left and right hemispheric stroke (82.9% vs
82.1%).
Hierarchy of presenting symptoms
The item ‘arm/paresis’ was by far the most frequent
sign in all patients with stroke (aged 18–55 years), and
‘speech’ the second (ﬁgure 2). Both items together
were covering almost 75% of all recruited stroke and
patients with TIA. Under hierarchic perspective the fre-
quency of the ‘face’ item (0.2%) becomes irrelevant if
the four most common signs of stroke ‘arm/paresis’
(57.7%), ‘speech’ (16.9%), ‘vertigo’ (10.6%) and ‘som-
atosensory deﬁcit’ (6.8%) were prior sequentially used
as selection criteria.13 14 Hemianopia occurred in
general with a frequency of 14.4% but only 3.2% of the
cases experienced this symptom independent from
arm/paresis, speech, vertigo or somatosensory deﬁcits.
Common stroke signs in young patients such as head-
ache, leg paresis and diplopia were seldom or not inde-
pendently differentiated from other stroke signs.
DISCUSSION
Principal findings
Frequency of presenting symptoms
In our cohort the FAST symptoms could be traced in
76.5% of all cases. This is notably less than in a previ-
ously reported study in which study nurses screened
retrospectively the medical records of 3498 stroke cases
who presented in an acute care hospital.4 The ‘capture
rate’ in this study was 88.9% for all strokes including
haemorrhage and even higher for ischaemic stroke and
TIA (91.1% and 91.8%, respectively). Interestingly
Kleindorfer et al4 found that cases missed by FAST
tended to be signiﬁcantly younger than cases with FAST
symptoms (mean 68.9 vs 71.5 years). Even though
Kleindorfer et al investigate a general stroke population,
in our selected cohort with younger patients (median
age 46 years), we observed a comparable trend with sig-
niﬁcantly fewer patients presenting with symptoms
covered by FAST in younger age groups. Therefore, clin-
ical signs included in FAST might be less prevalent in
younger patients with stroke.
With respect to FAST signs there was no gender differ-
ence in stroke presentation. Other presenting symptoms
such as headache, nausea/vomiting and somatosensory
deﬁcits occurred more frequently in women. This spe-
ciﬁc feature could not be explained by larger number of
vertebra-basilar strokes in women. Gender differences in
these symptoms were also signiﬁcant when patients with
TIA were excluded. In a previous study on gender differ-
ences in acute stroke symptoms a higher prevalence of
symptoms termed ‘non-traditional’ (pain, mental status
change, light-headedness, headache, non-neurological
symptoms) could be registered in women.7 However,
there were no differences observed regarding traditional
symptoms such as hemiparesis, aphasia, facial weakness,
hemibody numbness, which is in line with our ﬁndings.7
Clinical signs clustered according to the FAST scheme
disclosed more patients with stroke with increasing
stroke severity. Nearly all cases who received thromboly-
sis irrespective of gender were indicated by symptoms
included in FAST. This is of major interest, because a
recent meta-analysis indicated that women with stroke
had 30% lower odds of receiving tissue plasminogen
activator thought possibly to result from different
symptom presentation in women.
Hierarchy of presenting symptoms
‘Arm/paresis’ and ‘Speech’ are by far the most relevant
ischaemic stroke signs. ‘Face’ can be quantitatively
neglected, because it occurred as an isolated symptom
very rarely. Nevertheless, 34.7% of patients with at least
one FAST symptom report all three FAST symptoms,
meaning that ‘Face’ is rare as an isolated symptom but
often accompanied by ‘Arm/Paresis’ or ‘Speech’.
Similarly, headache is not relevant to identify ischaemic
stroke but may characterise cases with subarachnoid
Table 3 Frequency of presenting symptoms not accounted for FAST
All Men Women
p Value
18–44 years 44–55 years
p ValuePer cent Per cent Per cent Per cent Per cent
Vertigo (n=4496) 29.4 29.5 29.4 0.836 30.5 28.7 0.329
Hemianopia (n=4535) 14.4 14.2 14.7 0.615 16.3 13.1 0.006
Diplopia (n=4502) 10.3 10.8 9.6 0.201 10.2 10.4 0.840
Headache (n=4499) 31.9 27.1 38.7 <0.0001 38.8 27.3 <0.001
Nausea/vomiting (n=4516) 19.8 18.0 22.3 <0.001 22.3 18.1 0.001
Amaurosis fugax (n=4505) 2.3 2.0 2.8 0.113 2.4 2.3 0.760
Somatosens deficit (n=4147) 55.9 54.4 58.1 0.032 59.4 53.6 <0.001
Gaze deviation (n=4534) 8.4 8.7 7.9 0.320 8.5 8.3 0.884
Leg paresis (n=4535) 35.0 35.3 34.5 0.543 33.2 36.1 0.095
FAST, face, arm, speech, timely.
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haemorrhage. Remarkably, one single stroke sign
(‘Arm/Paresis’) was effective enough to select 86.7% of
patients in the subgroup of patients who underwent
thrombolytic therapy. However, clinical signs included in
the FAST scheme were absent in 23.5% of patients with
stroke included in sifap1. Moreover 37.7% of patients
with TIA had symptoms other than those mentioned by
FAST. Sign included in the FAST scheme were also less
frequent in young patients with vertebrobasilar infarc-
tions (64.5%). This is relevant, because ‘non-FAST’ signs
are frequently seen as ﬁrst symptoms of progressing
stroke, especially in basilar thrombosis and patients
missed by FAST do not necessarily have a benign
outcome.4
Other recognition instruments
The ASA Stroke Warning Signs5 emphasise the term
‘sudden’ as preﬁx, and add a broad spectrum of signs
(weakness of face, arm or leg, confusion, trouble speak-
ing or understanding, trouble seeing in one or both
eyes, trouble walking, dizziness, loss of balance or coord-
ination, severe headache). This extensive summary of
neurological symptoms is likely to cover every brain
injury. This kind of messaging takes advantage of the
fact that acute onset (‘sudden’) is the most discriminat-
ing factor between stroke and non-stroke and targets
96% of all strokes and TIA but can include 47% of dif-
ferential non-stroke diagnoses.1 The Cincinnati Prehospital
Stroke Scale (CPSS)3 is a 3-item scale derived from a sim-
pliﬁcation of the National Institutes of Health (NIH)
Stroke Scale. It evaluates facial droop and arm drift,
speech is tested by asking the patient to repeat sen-
tences. Thereby the CPSS design is very similar to FAST9
and its reproducibility has proven excellent among pre-
hospital care providers.3 In agreement with our ﬁndings,
the CPSS has also proven high validity to identify candi-
dates for thrombolysis and strokes preferably in the
anterior circulation. The Los Angeles Prehospital Stroke
Screen (LAPPS)2 considers unilateral motor weakness
(‘facial smile/grimace’, hand grip and arm strength/
drift) as well as four screening criteria (Age >45, history
of seizure disorder absent, symptoms duration less than
24 h, not wheelchair user or bedridden prior to the
event) and a glucose measurement. It was designed to
allow prehospital personnel to rapidly identify most
common patients with stroke and exclude those unlikely
to qualify for or beneﬁt from acute interventions.
Thereby patients with stroke below 45 years or with
longer symptom duration were purposefully not tar-
geted. The Melbourne Ambulance Stroke Screen (MASS)6
combines clinical signs of the CPSS with the LAPPS
screening criteria. The ROSSIER scale1 lists ﬁve key
signs scoring positive (asymmetric facial/arm/leg weak-
ness, speech disturbances and visual ﬁeld defect) and
two items scoring negative (loss of consciousness and
syncope, seizure activity) adding to a total score ranging
between −2 and +5. The purpose of the ROSSIER
design was to develop a simple and practical instrument
Ta
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for emergency room physicians in order to reduce the
number of non-stroke referrals from emergency room to
stroke unit.
Stroke recognition instruments must be differentiated
with regard to the addressee. For public education and
campaigns there is no choice but to promote a selected
number of clinical signs. Additional assessments (ie,
glucose measurements) to rule out non-strokes or stroke
subgroups are reserved for paramedic use or for triage
purposes in hospital.
Strengths and weaknesses of the study
The sifap1 study is by far the largest prospective multi-
center study analysing presenting stroke symptoms in
the young with broad clinical work up including MRI.
Age limit up to 55 years allows exploring subgroups with
increasing age including patients with risk factor and
aetiology proﬁles resembling those found in elderly
patients with stroke.10 Therefore, the ﬁndings may be
extrapolated to some extent to the stroke population in
general. Nevertheless there are some limitations regard-
ing this study: The main purpose of sifap1 was not to val-
idate a stroke recognition instrument. Therefore, ‘FAST
wording’ was primarily not covered with a speciﬁc item
in the CRF. Instead we asked for paresis directly after
CVE and employed the NIH Stroke Scale immediately
after hospital admission (median delay: one day).
Assessments ruling out stroke mimics (ie, blood glucose
level) inﬂuence speciﬁcity but cannot be used for public
education.6 Since we excluded stroke mimics by deﬁn-
ition, our study is not designed to calculate for positive
and negative predictive values of distinct stroke signs.
Moreover, there is a problem in general to calculate for
false-negative diagnoses, that is, undiagnosed strokes in a
population under survey. It has to be noted also, that we
did not consider haemorrhage, subarachnoid haemor-
rhage or venous thrombosis in our calculations.
Addressing all these strokes types may further add to
complexity and dilute the awareness message. The FAST
scheme was develop to screen for potential stroke
victims in a preclinical setting.9 In contrast our patients
were included after admission to a neurological depart-
ment. This needs to be taken into account when inter-
preting our results.
Extensive MRI documentation allowed us to validate
the clinical stroke diagnosis and constituted a robust
additional aspect in identifying presenting symptoms in
acute young patients with stroke. One-third of vertebra-
basilar strokes and transient attacks could not be
visualised on MRI. In these cases the appraisal of an
experienced neurologist was decisive. Notably, there was
no relevant difference regarding signs included in the
FAST scheme comparing patients with and without
proven MRI lesions.
Implications for public campaigns
Instruments that help the lay public to identify stroke in
prehospital setting are elementary to trigger early treat-
ment. Our study in patients with stroke (aged 18–
55 years) proves that symptoms considered in the FAST
scheme may be useful for identifying young patients
with stroke. Especially young patients with stroke eligible
for thrombolysis might be targeted by a FAST evaluation.
In contrast, clustering only clinical symptoms according
to FAST, it might be less effective in young patients with
stroke with TIA and infarcts in the posterior circulation.
Figure 2 Initial presenting
symptoms (shown as a
percentage of all cases).
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Since risk factors and aetiology proﬁles in the sifap1
cohort resembled those found in elderly patients with
stroke,10 conclusions from our study may be also valid in
older age groups.
Design and usefulness of stroke recognition instru-
ments depend strongly on the context and the target
group to be addressed. The proper diagnosis of stroke
requires profound clinical knowledge, which cannot be
expected from lay persons or ambulance paramedics.
On one hand simpliﬁed but speciﬁc signs are needed
for public campaigns, on the other hand stroke recogni-
tion in prehospital settings cannot be simpliﬁed without
losing a substantial number of patients. Obviously, signs
such as ‘Vertigo’ and ‘Somatosensory Deﬁcits’ target
much more patients with stroke but coincidently capture
more stroke mimics and thereby dilute the message and
burden the healthcare system.
It is important to recognise that sudden neurological
symptoms need expeditious referral and neurological
expertise, because sudden neurological diseases other
than stroke may represent emergencies as well.
Messaging in public awareness programmes is therefore
subject to more complex considerations. Besides catchy
wording, frequency of symptoms, capture rates and posi-
tive and negative predictive values, the capacity and
readiness of regional healthcare systems to cope with
stroke mimics will enhance public campaigns.
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